Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
29 May 2025
With Gerald Posner
Global
Gerald Posner — Pulitzer Prize finalist, former lawyer, and veteran pharmaceutical investigator — draws documented parallels between the opioid crisis and the puberty blocker pipeline. Profit incentives, off-label prescribing, silenced researchers, and institutional capture of regulatory bodies have, he argues, allowed ideology to displace evidence in gender medicine — a pattern now under formal scrutiny in several European countries following systematic evidence reviews.
Gerald Posner has spent decades following pharmaceutical money. A Pulitzer Prize finalist, former lawyer, and author of investigations into the drug industry's role in the opioid epidemic, Posner brings a forensic methodology to gender medicine that most mainstream journalists have declined to apply. In this episode, he explains not only what the evidence shows about the puberty blocker pipeline, but why so little of it reaches the public — and who benefits from that silence. The pharmaceutical parallel Posner draws is precise rather than rhetorical. The opioid crisis was enabled by off-label prescribing practices that allowed drugs to be used far beyond their tested indications, commercial interests that outran clinical evidence, and a regulatory environment slow to respond. Posner argues that puberty-blocking drugs — approved for other conditions and repurposed for gender-distressed adolescents — are being dispensed through exactly the same mechanisms, without the long-term safety data that routine prescribing would demand. An FDA loophole enabling this, he explains, receives almost no scrutiny in mainstream journalism. The episode examines what internal WPATH communications reveal about the relationship between political considerations and clinical guidance. Posner discusses how the organisation long treated as the authoritative international voice on gender medicine has been subject to external influence that raises serious questions about the integrity of its published standards. This is not an abstraction: WPATH protocols have been cited in clinical guidelines and legal proceedings across multiple countries, including European jurisdictions where courts and health authorities are now interrogating the evidence base underlying those guidelines. Postner is candid about the professional costs of pursuing this kind of reporting. Publishers have declined manuscripts. Journalists who investigated the subject found their pitches rejected or their work quietly buried. The mechanisms of suppression are not always explicit; more often they involve an ambient awareness of which topics carry career risk, which sources will be dismissed as motivated, and which investigations will be characterised as harmful regardless of their factual rigour. The result is a substantial gap in the public record on an intervention being administered to tens of thousands of minors worldwide. The conversation carries particular weight alongside Europe's own evidence reckonings. The Cass Review, published in 2024, subjected paediatric gender medicine to the systematic scrutiny that Posner argues pharmaceutical journalism failed to provide. Its central finding — that the evidence for puberty blockers and cross-sex hormones in minors is of very low certainty — prompted service suspensions in England and Wales, guideline revisions across Nordic countries, and ongoing legal challenges in other European jurisdictions. Posner's framework of pharmaceutical industry analysis helps explain why that reckoning took so long to arrive, and why the medical institutions most invested in existing protocols have been the slowest to engage with it.
